Science Explorer Back to mapMap
Discussion
Company · Waltham · United States

Immunitas Therapeutics (United States)

Research works
5
▲ 900% vs 2018-21
Citations
51
11.3 per fractional work
Top-10% rate
9.9%
all institutions 10.0%
Open access
81%
world 40%
International
37%
world 18%

Not ranked overall: Immunitas Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Immunitas Therapeutics (United States) work in?

In all years, 66% of research at Immunitas Therapeutics (United States) is in Health Sciences, 34% in Life Sciences. Its largest fields are Medicine (66%), Immunology and Microbiology (32%), Biochemistry, Genetics and Molecular Biology (2%). It does 1.5× the world's share of Health Sciences.

Life Sciences34%Health Sciences66%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 2 domains and 3 fields, with their numbers
    1. Medicine365.9%
    1. Immunology and Microbiology131.8%
    2. Biochemistry, Genetics and Molecular Biology02.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Who are the top researchers at Immunitas Therapeutics (United States)?

Ranked on the quality score, Ming Tang lead among researchers whose main affiliation is Immunitas Therapeutics (United States).

  1. 1 Ming Tang United States · #1,350,769 worldwide 334 citations · 70 works
All ranked researchers at Immunitas Therapeutics (United States)

What are the most cited papers from Immunitas Therapeutics (United States)?

The most cited paper from Immunitas Therapeutics (United States) is "Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion" (Chris J. Frangieh et al., 2021), with 289 citations. Next come "Clonally expanded, GPR15-expressing pathogenic effector T H 2 cells are associated with eosinophilic esophagitis" (120) and "Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS" (39).

Most cited papers
#PaperReleasedCitations
1 Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion Chris J. Frangieh et al. · Nature Genetics Open access Mar 2021 289
2 Clonally expanded, GPR15-expressing pathogenic effector T H 2 cells are associated with eosinophilic esophagitis Duncan M. Morgan, Bert Ruiter, Neal Patrick Smith et al. · Science Immunology Open access 10 Aug 2021 120
3 Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS Jens Kühle, Nadia S Daizadeh, Pascal Benkert et al. · Multiple Sclerosis Journal Open access 11 Aug 2021 39
4 Methionine Enkephalin (MENK) Inhibits tumor growth through regulating CD4+Foxp3+ Regulatory T cells (Tregs) in mice Xuan Li, Yiming Meng, Nicolas P. Plotnikoff et al. · Cancer Biology & Therapy Open access 20 Feb 2015 39
5 Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity Simone Punt et al. · Cancer Immunology Immunotherapy Open access 29 Oct 2020 34
All 9 most cited papers, with filters and sorting

Which research topics does Immunitas Therapeutics (United States) publish most on?

By volume in 2022-now: Immune Cell Function and Interaction, CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research and Cytokine Signaling Pathways and Interactions.

  1. 1 Immune Cell Function and Interaction Immunology 1 works
  2. 2 CAR-T cell therapy research Oncology 1 works
  3. 3 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 0 works
  4. 4 Cytokine Signaling Pathways and Interactions Oncology 0 works
  5. 5 Chronic Kidney Disease and Diabetes Nephrology 0 works
  6. 6 Renin-Angiotensin System Studies Cardiology and Cardiovascular Medicine 0 works
  7. 7 Renal Diseases and Glomerulopathies Nephrology 0 works
  8. 8 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 0 works
  9. 9 Biosimilars and Bioanalytical Methods Immunology 0 works
  10. 10 Immunotherapy and Immune Responses Immunology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available80.8%not open19.2%

World: 40% of research is openly available.

with international co-authors36.8%domestic only63.2%

World: 18% is written across borders.

How has Immunitas Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 900% higher than in 2018-2021.

still counting20202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Waltham

All research institutions in Waltham

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Immunitas Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.